Journal Article (Review Article)

DZNE-2022-00084

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Recent advances in cancer immunotherapy.

Sun, Q. ; Melino, G.DZNE* ; Amelio, I. ; Jiang, J. ; Wang, Y. ; Shi, Y.

2021
Springer [New York]

This record in other databases:    

Please use a persistent id in citations: doi:10.1007/s12672-021-00422-9

Abstract: Cancer immunotherapy represents a major advance in the cure of cancer following the dramatic advancements in the development and refinement of chemotherapies and radiotherapies. In the recent decades, together with the development of early diagnostic techniques, immunotherapy has significantly contributed to improving the survival of cancer patients. The immune-checkpoint blockade agents have been proven effective in a significant fraction of standard therapy refractory patients. Importantly, recent advances are providing alternative immunotherapeutic tools that could help overcome their limitations. In this mini review, we provide an overview on the main steps of the discovery of classic immune-checkpoint blockade agents and summarise the most recent development of novel immunotherapeutic strategies, such as tumour antigens, bispecific antibodies and TCR-engineered T cells.

Keyword(s): Cancer immunotherapy ; Cancer survival ; Immune check point blockade ; KRas ; T cell receptor ; p53

Note: Journal: Discover Oncology, ISSN: 2730-6011

---

Contributing Institute(s):

1. Synaptic Connectivity and Neurodegeneration (AG Nicotera)

Research Program(s):

1. 351 - Brain Function (POF4-351) (POF4-351)

Appears in the scientific report 2021

---

Database coverage:
; ; ; ; Article Processing Charges ; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; DOAJ Seal ; Essential Science Indicators ; Fees ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---